JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB196883

Anti-ERK1 + ERK2 抗体

Anti-ERK1 + ERK2 antibody

Be the first to review this product! Submit a review

|

(47 Publications)

Rabbit Polyclonal ERK2 antibody. Suitable for WB and reacts with Mouse, Human samples. Cited in 47 publications. Immunogen corresponding to Synthetic Peptide within Human MAPK3.

別名を表示する

ERK2, PRKM1, PRKM2, MAPK1, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, MAP kinase isoform p42, Mitogen-activated protein kinase 2, ERK-2, p42-MAPK, MAP kinase 2, MAPK 2

3 Images
Western blot - Anti-ERK1 + ERK2 antibody (AB196883)
  • WB

Supplier Data

Western blot - Anti-ERK1 + ERK2 antibody (AB196883)

All lanes:

Western blot - Anti-ERK1 + ERK2 antibody (ab196883) at 1/500 dilution

Lane 1:

NIH/3T3 (Mouse embryo fibroblast cell line) cell extract

Lane 2:

NIH/3T3 (Mouse embryo fibroblast cell line) cell extract with synthesized peptide

Predicted band size: 41 kDa,46 kDa

Observed band size: 46 kDa

false

Western blot - Anti-ERK1 + ERK2 antibody (AB196883)
  • WB

Supplier Data

Western blot - Anti-ERK1 + ERK2 antibody (AB196883)

All lanes:

Western blot - Anti-ERK1 + ERK2 antibody (ab196883) at 1/500 dilution

All lanes:

K562 (Human chronic myelogenous leukemia cell line from bone marrow) cell extract

Predicted band size: 41 kDa

false

Western blot - Anti-ERK1 + ERK2 antibody (AB196883)
  • WB

CiteAb

Western blot - Anti-ERK1 + ERK2 antibody (AB196883)

ERK1 + ERK2 western blot using anti-ERK1 + ERK2 antibody ab196883. Publication image and figure legend from Liang, R. N., Li, P. S., et al., 2017, Evid Based Complement Alternat Med, PubMed 28656053.

ab196883 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab196883 please see the product overview.

The suppressive effect of PCJNF-containing serum was mediated by JNK signaling pathway in EESCs. (a) EESCs were treated with 20% PCJNF-containing serum and different controls for 0, 24, 48, 72, and 96 h, respectively. The cell viability was assessed by CCK8 assay. Compared with different control groups (CONT, DMSO, and NS), 20% PCJNF-containing serum had significant suppressed effect on cell viability after 24 h, while the JNK inhibitor SP600125 attenuated this effect only after 48 h. The experiment was performed in triplicate. (b) Meanwhile, JNK inhibitor SP600125 deactivates the JNK signaling pathway in EESCs, when compared with different controls (CONT, DMSO, and NS). While there was no significant difference of cell proliferation in EESCs between the "NS" and "NS + SP600125" group (P > 0.05). (c) The total and phosphorylated ERK and p38 of EESCs did not change markedly, when compared with different controls. The experiment was performed in triplicate. NS : rat serum from saline treatment; PCJNF : rat serum with PCJNF treatment.

false

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Mouse, Human

アプリケーション

WB

applications

免疫原

Synthetic Peptide within Human MAPK3. The exact immunogen used to generate this antibody is proprietary information.

P27361

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" } } }

下記製品もご検討ください

AB184699

Anti-ERK1 + ERK2 antibody [EPR17526]

5
1 Reviews
製品ページを見る
こちらの製品も推奨する理由

私たちは、より高品質な製品をお届けするために、製品構成を常に改善しています。今回ご紹介する代替製品は、性能の向上、使いやすさや利便性の向上、またはより早くお届けできる点などを踏まえて選定しています。

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Immunogen
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

ERK1 and ERK2 also known as MAPK3 and MAPK1 respectively are protein kinases involved in the mitogen-activated protein kinase (MAPK) signaling pathway. They share high sequence identity and exhibit similar functions. ERK1 has a molecular weight of approximately 44 kDa while ERK2 weighs around 42 kDa. Both are expressed ubiquitously in various tissues playing roles in diverse cellular processes. These proteins often detected through ERK1/2 western blot analyses present similar ERK protein size and ERK molecular weight characteristics relevant during protein expression studies.
Biological function summary

ERK1 and ERK2 play key roles in cell proliferation differentiation and survival. They form part of a cascade that includes upstream activators such as MEK1/2 and downstream targets including transcription factors. As components of the MAPK signaling complex ERK1/2 regulate gene expression through phosphorylation events impacting cellular responses to various stimuli. Their activation often hinges on growth factors cytokines and stress signals facilitating cellular adaptation to environmental changes.

Pathways

Regarding pathways ERK1/2 sit within the MAPK/ERK pathway and are significant in the Ras/Raf/MEK/ERK cascade one of the foremost signaling mechanisms in cells. They interact with several proteins including Ras and Raf which modulate their activation. This pathway is important for transmitting signals from the cell surface to the DNA in the cell nucleus impacting gene regulation and cell fate decisions. ERK1/2 proteins therefore serve as critical nodes linking extracellular signals to cellular responses ensuring balanced cell function.

ERK1/2 play significant roles in cancer and neurodegenerative diseases. Their overactivation is often linked to oncogenic processes contributing to cell proliferation in cancers. Mutations or dysregulation within the MAPK/ERK pathway including ERK1/2 frequently associate with tumorigenesis. Additionally in neurodegenerative disorders like Alzheimer's disease altered ERK1/2 activity may impact neuronal survival and function often through interaction with amyloid-beta and tau proteins further illustrating their importance in disease pathophysiology.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1 and FXR1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in response to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation. Phosphorylates CDK2AP2 (By similarity).. Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] consensus sequence. Repress the expression of interferon gamma-induced genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity is independent of kinase activity.
See full target information MAPK1

追加のターゲット

MAPK3

文献 (47)

Recent publications for all applications. Explore the full list and refine your search

Environmental toxicology 38:2002-2010 PubMed37219039

2023

TRIM29 facilitates proliferation and malignancy of cholangiocarcinoma cells by activating MAPK and β-catenin pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Yang,Wenqing Bao,Haiyan Diao,Shaofei Yang,Lin Qiu,Chunjing Xu,Bin Zhao

Cell cycle (Georgetown, Tex.) 22:718-731 PubMed36404682

2022

High expression of IGHG1 promotes breast cancer malignant development by activating the AKT pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yongmei Jin,Lin Qiu,Wenqing Bao,Minhao Lu,Feng Cao,Hanchen Ni,Bin Zhao

Frontiers in bioscience (Landmark edition) 27:62 PubMed35227005

2022

Effect of Low-Level Er: YAG (2940 nm) laser irradiation on the photobiomodulation of mitogen-activated protein kinase cellular signaling pathway of rodent cementoblasts.

Applications

Unspecified application

Species

Unspecified reactive species

Jiawen Yong,Pingping Li,Isaac Kably Mizrahi,Rene Franzen,Sabine Groeger,Sabine Ruf,Norbert Gutknecht,Márcia Martins Marques

Frontiers in oncology 11:657008 PubMed34336654

2021

N2E4, a Monoclonal Antibody Targeting Neuropilin-2, Inhibits Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma Suppressing FAK/Erk/HIF-1α Signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Li Wang,Lanlan Wang,Shengyu Wang,Zonglang Zhou,Zongjunlin Liu,Peilan Xu,Xian Luo,Ting Wu,Fanghong Luo,Jianghua Yan

Oncology reports 45: PubMed33786627

2021

Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK.

Applications

Unspecified application

Species

Unspecified reactive species

Xin Liang,Jianxin Ju

Journal of molecular endocrinology : PubMed32698141

2020

Long non-coding RNA H19 contributes to wound healing of diabetic foot ulcer.

Applications

Unspecified application

Species

Unspecified reactive species

Bo Li,Yue Zhou,Jing Chen,Tingting Wang,Zhijuan Li,Yili Fu,Changlong Bi,Aixia Zhai

Cell cycle (Georgetown, Tex.) 19:990-999 PubMed32266863

2020

Overexpression of HIF-1α protects PC12 cells against OGD/R-evoked injury by reducing miR-134 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Hongliang Zhang,Xianming Liu,Fengyu Yang,Dekui Cheng,Wei Liu

Experimental and therapeutic medicine 19:762-770 PubMed31853327

2019

Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Daye Zhang,Yongxiang Zhang,Zeyuan Cai,Ying Tu,Zhansong Hu

EBioMedicine 46:66-78 PubMed31383552

2019

MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Wei-Wei Wang,Zhi-Hua Zhao,Li Wang,Pan Li,Kui-Sheng Chen,Jian-Ying Zhang,Wen-Cai Li,Guo-Zhong Jiang,Xiang-Nan Li

Anticancer research 39:3595-3599 PubMed31262884

2019

Perampanel Inhibits Neuroblastoma Cell Proliferation Through Down-regulation of AKT and ERK Pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Akifumi Nozawa,Michio Ozeki,Mikako Matsuoka,Mina Nakama,Shiho Yasue,Saori Endo,Norio Kawamoto,Hidenori Ohnishi,Toshiyuki Fukao
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

関連製品

Select an associated product type
Alternative Product
Primary Antibodies

AB210460

Alexa Fluor® 594 Anti-ERK1 + ERK2 antibody [EPR17526]

primary-antibodies

alexa-fluor-594-erk1-erk2-antibody-epr17526-ab210460

0

(0 reviews)

Alternative Product
Primary Antibodies

AB210044

Alexa Fluor® 405 Anti-ERK1 + ERK2 antibody [EPR17526]

primary-antibodies

alexa-fluor-405-erk1-erk2-antibody-epr17526-ab210044

0

(0 reviews)

Alternative Product
Primary Antibodies

AB208564

Alexa Fluor® 488 Anti-ERK1 + ERK2 antibody [EPR17526]

primary-antibodies

alexa-fluor-488-erk1-erk2-antibody-epr17526-ab208564

0

(0 reviews)

Alternative Product
Primary Antibodies

AB208881

Alexa Fluor® 647 Anti-ERK1 + ERK2 antibody [EPR17526]

primary-antibodies

alexa-fluor-647-erk1-erk2-antibody-epr17526-ab208881

0

(0 reviews)

Alternative Product
Primary Antibodies

AB209321

HRP Anti-ERK1 + ERK2 antibody [EPR17526]

primary-antibodies

hrp-erk1-erk2-antibody-epr17526-ab209321

0

(0 reviews)

Alternative Product
Primary Antibodies

AB218017

Anti-ERK1 + ERK2 antibody [EPR17526] - BSA and Azide free

primary-antibodies

erk1-erk2-antibody-epr17526-bsa-and-azide-free-ab218017

0

(0 reviews)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com